AbbVie said it completed the public offering of senior notes in four series: February 26, 2025, due 2028, due 2030, due 2035 and due 2055, with coupons of 4.650%, 4.875%, 5.200% and 5.600%.

1. 01

   AbbVie said it completed the public offering of senior notes in four series: February 26, 2025, due 2028, due 2030, due 2035 and due 2055, with coupons of 4.650%, 4.875%, 5.200% and 5.600%.

2. 02

   The company said it issued notes with aggregate principal amounts of $1,250,000,000 due 2028, $1,000,000,000 due 2030, $1,000,000,000 due 2035 and $750,000,000 due 2055.

3. 03

   It said each series will mature on March 15 of the applicable year. It added that the notes are unsecured, unsubordinated obligations that rank equally in right of payment with all of its existing and future unsecured, unsubordinated indebtedness.

4. 04

   AbbVie said it may redeem each series before the applicable Par Call Date at the redemption price set forth in the indenture, and on or after that date at 100% of the principal amount plus accrued and unpaid interest. It also said the indenture contains covenants, including limits on liens securing funded indebtedness and on consolidations, mergers and asset conveyances.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.